It recorded a net loss of $183.8 million. Diluted earnings per share were -$2.06.
USD in millions, except per-share amounts and margins. The percent under a figure is the change from the year before.
| Line |
FY 2026
Jun 30, 2026
|
FY 2025
Dec 31, 2025
|
FY 2024
Dec 31, 2024
|
FY 2023
Dec 31, 2023
|
FY 2022
Dec 31, 2022
|
FY 2021
Dec 31, 2021
|
|---|---|---|---|---|---|---|
| Research and development |
155
+67.9%
|
118
+80.2%
|
65
+25.3%
|
52
+44.1%
|
36
+4.0%
|
35
|
| Selling, general and administrative |
73
+90.8%
|
49
+26.0%
|
39
-7.5%
|
42
+38.4%
|
30
-48.9%
|
59
|
| Operating income |
-228
-74.6%
|
-166
-60.0%
|
-104
-10.7%
|
-94
-41.5%
|
-66
+29.3%
|
-94
|
| Foreign currency gain (loss) |
-0
+6.7%
|
-0
+79.5%
|
-1
-506.4%
|
0
-19.5%
|
0
+326.7%
|
-0
|
| Other non-operating income (expense) |
-126
-899.0%
|
-17
-267.1%
|
-5
-155.3%
|
-2
-119.6%
|
10
+2912.7%
|
-0
|
| Pretax income |
—
|
-184
-69.1%
|
-109
-13.5%
|
-96
-68.6%
|
-57
+39.7%
|
-94
|
| Income tax |
—
|
0
|
—
|
—
|
—
|
-1
|
| Net income |
-354
-208.9%
|
-184
-69.1%
|
-109
-13.5%
|
-96
-68.6%
|
-57
+39.0%
|
-93
|
| Basic EPS |
-3.49
-152.8%
|
-2.06
-33.8%
|
-1.54
+36.9%
|
-2.44
-32.6%
|
-1.84
|
—
|
| Diluted EPS |
-3.52
-158.0%
|
-2.06
-33.8%
|
-1.54
+36.9%
|
-2.44
-32.6%
|
-1.84
|
—
|
| Weighted average shares, basic |
101
+22.2%
|
89
+26.8%
|
70
+79.9%
|
39
+26.9%
|
31
|
—
|
| Weighted average shares, diluted |
101
+19.7%
|
89
+26.8%
|
70
+79.9%
|
39
+26.9%
|
31
|
—
|
| Other measures | ||||||
| Interest coverage |
-45.33x
|
-30.34x
|
-45.52x
|
—
|
—
|
—
|
How these figures are calculated
Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and margins. Weighted average shares are in millions. Interest expense and finance costs are positive costs. A negative amount on a gain (loss) or income (expense) line is a loss or an expense. EBITDA is operating income plus depreciation and amortization. Interest coverage is operating income divided by interest expense. The first column is the trailing twelve months through the latest quarter. More on our methodology.
New to this? Read How to Read an Income Statement, With a Real Example.
Company profile
- Industry
- Medicinal Chemicals & Botanical Products (SIC 2833)
- Listed as
- DFTX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- British Columbia, Canada
- Headquarters
- New York, NY
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1813814
- Former names
- Mind Medicine (MindMed) Inc. (until Jan 12, 2026)
Other Medicinal Chemicals & Botanical Products companies
- Regencell Bioscience Holdings Ltd RGC
- Curaleaf Holdings, Inc. CURLF
- Trulieve Cannabis Corp. TRLV
- Cronos Group Inc. CRON
- TFA Therapeutics, Inc. RAJAF
- Tilray Brands, Inc. TLRY
- SNDL Inc. SNDL
- Aurora Cannabis Inc ACB
Source: SEC EDGAR filings. This is company-reported data, not investment advice.